Tags

Type your tag names separated by a space and hit enter

Ivermectin 1% (CD5024) for the treatment of rosacea.
Expert Opin Pharmacother. 2018 Apr; 19(5):511-516.EO

Abstract

INTRODUCTION

Rosacea is a chronic and recurrent disease with a variety of cutaneous manifestations. The disorder is a centrofacial inflammatory dermatosis with significant financial, physical and psychological impacts. There are a number of topical, oral and systemic treatments available. Yet, treatment for rosacea remains difficult. The multifactorial nature of the disease combined with an incomplete understanding of the pathophysiology is challenging for providers and patients. Areas covered: This article provides an in-depth review of rosacea treatment and emerging use of ivermectin 1% cream for papulopustular rosacea based on multiple clinical trials. The PubMed database was searched using the combination of keywords "ivermectin, rosacea, and papulopustular." Expert opinion: Topical ivermectin 1% cream has emerged as a novel agent for treatment of papulopustular rosacea. The drug targets the Demodex mite which is increased in patients with rosacea. Though ivermectin 1% is a clinically efficacious medication, poor adherence continues to remain an issue due to topical application. Ultimately, the agent has the potential to be an effective drug when used as a single or combination agent. With the move to limit chronic antibiotic use, topical agents such as ivermectin 1% will continue to thrive as a specialized niche in the rosacea market.

Authors+Show Affiliations

a School of Medicine , Virginia Commonwealth University , Richmond , VA , USA.b Center for Dermatology Research, Department of Dermatology , Wake Forest School of Medicine , Winston-Salem , NC , USA. c Department of Pathology , Wake Forest School of Medicine , Winston-Salem , NC , USA. d Department of Social Sciences & Health Policy , Wake Forest School of Medicine , Winston-Salem , NC , USA.b Center for Dermatology Research, Department of Dermatology , Wake Forest School of Medicine , Winston-Salem , NC , USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

29544355

Citation

Sahni, Dev R., et al. "Ivermectin 1% (CD5024) for the Treatment of Rosacea." Expert Opinion On Pharmacotherapy, vol. 19, no. 5, 2018, pp. 511-516.
Sahni DR, Feldman SR, Taylor SL. Ivermectin 1% (CD5024) for the treatment of rosacea. Expert Opin Pharmacother. 2018;19(5):511-516.
Sahni, D. R., Feldman, S. R., & Taylor, S. L. (2018). Ivermectin 1% (CD5024) for the treatment of rosacea. Expert Opinion On Pharmacotherapy, 19(5), 511-516. https://doi.org/10.1080/14656566.2018.1447562
Sahni DR, Feldman SR, Taylor SL. Ivermectin 1% (CD5024) for the Treatment of Rosacea. Expert Opin Pharmacother. 2018;19(5):511-516. PubMed PMID: 29544355.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ivermectin 1% (CD5024) for the treatment of rosacea. AU - Sahni,Dev R, AU - Feldman,Steven R, AU - Taylor,Sarah L, Y1 - 2018/03/16/ PY - 2018/3/17/pubmed PY - 2018/6/1/medline PY - 2018/3/17/entrez KW - Adherence KW - Demodex KW - clinical trial KW - ivermectin 1% KW - papulopustular rosacea KW - standardization SP - 511 EP - 516 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 19 IS - 5 N2 - INTRODUCTION: Rosacea is a chronic and recurrent disease with a variety of cutaneous manifestations. The disorder is a centrofacial inflammatory dermatosis with significant financial, physical and psychological impacts. There are a number of topical, oral and systemic treatments available. Yet, treatment for rosacea remains difficult. The multifactorial nature of the disease combined with an incomplete understanding of the pathophysiology is challenging for providers and patients. Areas covered: This article provides an in-depth review of rosacea treatment and emerging use of ivermectin 1% cream for papulopustular rosacea based on multiple clinical trials. The PubMed database was searched using the combination of keywords "ivermectin, rosacea, and papulopustular." Expert opinion: Topical ivermectin 1% cream has emerged as a novel agent for treatment of papulopustular rosacea. The drug targets the Demodex mite which is increased in patients with rosacea. Though ivermectin 1% is a clinically efficacious medication, poor adherence continues to remain an issue due to topical application. Ultimately, the agent has the potential to be an effective drug when used as a single or combination agent. With the move to limit chronic antibiotic use, topical agents such as ivermectin 1% will continue to thrive as a specialized niche in the rosacea market. SN - 1744-7666 UR - https://brain.unboundmedicine.com/medline/citation/29544355/Ivermectin_1__CD5024__for_the_treatment_of_rosacea_ DB - PRIME DP - Unbound Medicine ER -